The first compound library comprising novel small molecules designed to target deubiquitylase enzymes

Click on the link below to download a non-confidential summary of DUBtarget™-001 which includes details of how the library was designed and initially characterised by screening it using DUBprofiler™:

DUBtarget-001 non-confidential summary download here

Ubiquigent Ltd and The Drug Discovery Unit at the University of Dundee have jointly developed the first commercially available compound library designed to target deubiquitylase (DUB) enzymes, DUBtarget-001.

The library has been screened against all the DUBs that form part our DUBprofiler – DUB affinity and selectivity profiling – platform.  These data, as well as the physical library, are now available to access to help inform starting points for drug development programmes.

We are now offering parties access to the library, associated data and further characterisation of the compound set using DUBprofiler to support their ubiquitin-system drug discovery programmes.

Commercial Offering

Ubiquigent is now seeking partners interested in gaining access to DUBtarget-001.

The library is available to be accessed in a number of ways, including:

In its physical form as either solid or DMSO stock solutions for those wishing to screen it using their in-house assay platforms

In a virtual form based on the data generated using DUBprofiler™

Ubiquigent Limited is a specialist developer and supplier of Drug Discovery Services, high quality Research Tools and Chemistry to the life science research community worldwide.

Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems.

The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.

Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The Company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.

Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the Company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.